Machine learning algorithms for identifying predictive variables of mortality risk following dementia diagnosis: a longitudinal cohort study.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
10 06 2023
Historique:
received: 14 02 2023
accepted: 02 06 2023
medline: 12 6 2023
pubmed: 11 6 2023
entrez: 10 6 2023
Statut: epublish

Résumé

Machine learning (ML) could have advantages over traditional statistical models in identifying risk factors. Using ML algorithms, our objective was to identify the most important variables associated with mortality after dementia diagnosis in the Swedish Registry for Cognitive/Dementia Disorders (SveDem). From SveDem, a longitudinal cohort of 28,023 dementia-diagnosed patients was selected for this study. Sixty variables were considered as potential predictors of mortality risk, such as age at dementia diagnosis, dementia type, sex, body mass index (BMI), mini-mental state examination (MMSE) score, time from referral to initiation of work-up, time from initiation of work-up to diagnosis, dementia medications, comorbidities, and some specific medications for chronic comorbidities (e.g., cardiovascular disease). We applied sparsity-inducing penalties for three ML algorithms and identified twenty important variables for the binary classification task in mortality risk prediction and fifteen variables to predict time to death. Area-under-ROC curve (AUC) measure was used to evaluate the classification algorithms. Then, an unsupervised clustering algorithm was applied on the set of twenty-selected variables to find two main clusters which accurately matched surviving and dead patient clusters. A support-vector-machines with an appropriate sparsity penalty provided the classification of mortality risk with accuracy = 0.7077, AUROC = 0.7375, sensitivity = 0.6436, and specificity = 0.740. Across three ML algorithms, the majority of the identified twenty variables were compatible with literature and with our previous studies on SveDem. We also found new variables which were not previously reported in literature as associated with mortality in dementia. Performance of basic dementia diagnostic work-up, time from referral to initiation of work-up, and time from initiation of work-up to diagnosis were found to be elements of the diagnostic process identified by the ML algorithms. The median follow-up time was 1053 (IQR = 516-1771) days in surviving and 1125 (IQR = 605-1770) days in dead patients. For prediction of time to death, the CoxBoost model identified 15 variables and classified them in order of importance. These highly important variables were age at diagnosis, MMSE score, sex, BMI, and Charlson Comorbidity Index with selection scores of 23%, 15%, 14%, 12% and 10%, respectively. This study demonstrates the potential of sparsity-inducing ML algorithms in improving our understanding of mortality risk factors in dementia patients and their application in clinical settings. Moreover, ML methods can be used as a complement to traditional statistical methods.

Identifiants

pubmed: 37301891
doi: 10.1038/s41598-023-36362-3
pii: 10.1038/s41598-023-36362-3
pmc: PMC10257644
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

9480

Informations de copyright

© 2023. The Author(s).

Références

J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
BMC Bioinformatics. 2016 Jul 22;17:288
pubmed: 27444890
Neurology. 2021 Apr 27;96(17):e2220-e2230
pubmed: 33741639
BMC Bioinformatics. 2008 Jan 10;9:14
pubmed: 18186927
J Am Med Dir Assoc. 2019 Mar;20(3):323-329.e2
pubmed: 30824220
Bioinformatics. 2009 Apr 1;25(7):890-6
pubmed: 19244389
J Neurol Sci. 2005 Mar 15;229-230:43-9
pubmed: 15760618
Sci Rep. 2018 Oct 25;8(1):15775
pubmed: 30361509
J Alzheimers Dis. 2021;81(3):1253-1261
pubmed: 33935077
Curr Alzheimer Res. 2018;15(14):1322-1330
pubmed: 30280666
J Alzheimers Dis. 2022;86(1):245-257
pubmed: 35034902
J Am Med Dir Assoc. 2018 Feb;19(2):154-161
pubmed: 28993049
Stat Sci. 2012;27(4):
pubmed: 24174707
J Alzheimers Dis. 2018;65(2):589-596
pubmed: 30056424
J Biomed Inform. 2002 Oct-Dec;35(5-6):352-9
pubmed: 12968784
Bioinformatics. 2009 Jul 1;25(13):1711-2
pubmed: 19398451
J Alzheimers Dis. 2014;41(2):467-77
pubmed: 24625796
Alzheimers Dement. 2018 Jul;14(7):944-951
pubmed: 29706487
Sci Rep. 2020 Nov 23;10(1):20410
pubmed: 33230128
J Am Med Dir Assoc. 2021 Feb;22(2):312-319.e3
pubmed: 33321077
Acta Psychiatr Scand. 2016 Nov;134(5):430-440
pubmed: 27586958
Comput Methods Programs Biomed. 2014 Nov;117(2):51-60
pubmed: 25224081
Lancet Public Health. 2022 Feb;7(2):e105-e125
pubmed: 34998485
Curr Alzheimer Res. 2020;17(10):881-892
pubmed: 33327915
Neural Netw. 2019 Nov;119:286-298
pubmed: 31499353
J Alzheimers Dis. 2018;61(3):1119-1128
pubmed: 29286925
Front Big Data. 2021 Nov 01;4:684794
pubmed: 34790895
Alzheimers Res Ther. 2021 Dec 2;13(1):197
pubmed: 34857046
Diagn Progn Res. 2020 Jun 04;4:6
pubmed: 32607451
JAMA Netw Open. 2019 Jul 3;2(7):e196972
pubmed: 31298717
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Neurology. 2020 Feb 4;94(5):e538-e548
pubmed: 31843808
Biostatistics. 2004 Jul;5(3):427-43
pubmed: 15208204
Int J Geriatr Psychiatry. 2021 Dec 17;37(2):
pubmed: 34921446
Eur J Clin Nutr. 2014 Nov;68(11):1204-9
pubmed: 25271014
Bioinformatics. 2015 Nov 15;31(22):3718-20
pubmed: 26209431
J Intern Med. 2021 Apr;289(4):508-522
pubmed: 32854138
J Am Med Dir Assoc. 2014 Jun;15(6):447.e1-7
pubmed: 24721339
BMC Geriatr. 2022 Mar 12;22(1):193
pubmed: 35279092
J Am Med Dir Assoc. 2021 Jul;22(7):1477-1483.e3
pubmed: 33309648
Bioinformatics. 2006 Jan 1;22(1):88-95
pubmed: 16249260
Lancet Neurol. 2016 Apr;15(5):455-532
pubmed: 26987701
PLoS One. 2015 Feb 19;10(2):e0116538
pubmed: 25695768
Can Geriatr J. 2022 Mar 02;25(1):66-71
pubmed: 35310474
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Stat Methods Med Res. 2017 Jun;26(3):1053-1077
pubmed: 25656552
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35
pubmed: 16897791
PLoS One. 2018 Mar 27;13(3):e0194889
pubmed: 29584784

Auteurs

Shayan Mostafaei (S)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden. shayan.mostafaei@ki.se.
Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden. shayan.mostafaei@ki.se.

Minh Tuan Hoang (MT)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.
Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.

Pol Grau Jurado (PG)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.

Hong Xu (H)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.

Lluis Zacarias-Pons (L)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.
Vascular Health Research Group of Girona (ISV-Girona), Institut Universitari d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAP Jordi Gol), Girona, Spain.
Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), Tenerife, Spain.

Maria Eriksdotter (M)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.
Aging and Inflammation Theme, Karolinska University Hospital, Stockholm, Sweden.

Saikat Chatterjee (S)

Division of Information Science and Engineering, School of Electrical Engineering and Computer Science, KTH Royal Institute of Technology, Stockholm, Sweden.

Sara Garcia-Ptacek (S)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden. sara.garcia-ptacek@ki.se.
Aging and Inflammation Theme, Karolinska University Hospital, Stockholm, Sweden. sara.garcia-ptacek@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH